A number of research firms have changed their ratings and price targets for Teva Pharmaceutical Industries Limited (NYSE: TEVA):

  • 9/18/2017 – Teva Pharmaceutical Industries Limited had its price target lowered by analysts at Royal Bank Of Canada from $21.00 to $15.00. They now have an “underperform” rating on the stock.
  • 9/18/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $17.00 price target on the stock.
  • 9/14/2017 – Teva Pharmaceutical Industries Limited had its “neutral” rating reaffirmed by analysts at UBS AG. They now have a $19.00 price target on the stock.
  • 9/14/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Maxim Group. They now have a $15.50 price target on the stock.
  • 9/13/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 9/13/2017 – Teva Pharmaceutical Industries Limited had its “buy” rating reaffirmed by analysts at Gabelli.
  • 9/12/2017 – Teva Pharmaceutical Industries Limited had its price target lowered by analysts at Jefferies Group LLC from $21.00 to $18.50. They now have a “hold” rating on the stock.
  • 9/11/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 9/11/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at BTIG Research from a “neutral” rating to a “buy” rating. They now have a $24.00 price target on the stock.
  • 9/11/2017 – Teva Pharmaceutical Industries Limited was given a new $17.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 9/6/2017 – Teva Pharmaceutical Industries Limited had its price target raised by analysts at JMP Securities from $13.00 to $14.00. They now have an “underperform” rating on the stock.
  • 9/5/2017 – Teva Pharmaceutical Industries Limited had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $27.00 price target on the stock.
  • 9/5/2017 – Teva Pharmaceutical Industries Limited had its “underperform” rating reaffirmed by analysts at Royal Bank Of Canada.
  • 9/1/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 8/31/2017 – Teva Pharmaceutical Industries Limited had its “neutral” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). They now have a $21.00 price target on the stock, down previously from $28.00.
  • 8/30/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $27.00 price target on the stock.
  • 8/25/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at TheStreet from a “c-” rating to a “d+” rating.
  • 8/23/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at Credit Suisse Group from a “neutral” rating to an “underperform” rating. They now have a $13.00 price target on the stock, down previously from $25.00.
  • 8/22/2017 – Teva Pharmaceutical Industries Limited had its “neutral” rating reaffirmed by analysts at Mizuho. They now have a $16.00 price target on the stock, down previously from $30.00.
  • 8/16/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating. They now have a $19.00 price target on the stock, down previously from $32.00.
  • 8/16/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 8/9/2017 – Teva Pharmaceutical Industries Limited had its “outperform” rating reaffirmed by analysts at Credit Suisse Group. They now have a $39.00 price target on the stock.
  • 8/9/2017 – Teva Pharmaceutical Industries Limited had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $27.00 price target on the stock, down previously from $31.00.
  • 8/9/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $26.00 price target on the stock, down previously from $33.00.
  • 8/9/2017 – Teva Pharmaceutical Industries Limited had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $28.00 price target on the stock, down previously from $43.00.
  • 8/9/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong sell” rating. According to Zacks, “Teva missed estimates for both earnings and sales in Q2. The company also slashed its 2017 earnings and sales outlook to reflect the challenging environment in the U.S. generics business and the continued deterioration in Venezuela. Teva also announced a 75% cut in its dividend. The U.S. generics industry’s competitive and pricing pressure is expected to continue in the near future. Teva is facing several other challenges in the form of generic competition for Copaxone, new competition for branded products, a high cost base and debt load and the sudden departure of its CEO. Also, Teva’s shares underperformed the generic industry this year so far. Nonetheless, Teva is progressing with its branded/generics drugs pipeline and is looking to strengthen its biosimilar pipeline. The Actavis Generics acquisition is contributing to the growth of the Generics unit. However, a clear path to growth is not visible.”
  • 8/8/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/7/2017 – Teva Pharmaceutical Industries Limited had its price target lowered by analysts at Barclays PLC from $38.00 to $23.00. They now have an “equal weight” rating on the stock.
  • 8/4/2017 – Teva Pharmaceutical Industries Limited had its “neutral” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $23.00 price target on the stock, down previously from $28.00.
  • 8/4/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at Royal Bank Of Canada from an “outperform” rating to an “underperform” rating. They now have a $21.00 price target on the stock, down previously from $37.00.
  • 8/4/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at Credit Suisse Group from an “outperform” rating to a “neutral” rating. They now have a $25.00 price target on the stock, down previously from $39.00.
  • 8/4/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at Cowen and Company from an “outperform” rating to a “market perform” rating. They now have a $30.00 price target on the stock, down previously from $50.00.
  • 8/4/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Maxim Group. They now have a $35.00 price target on the stock.
  • 8/4/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at Sanford C. Bernstein from an “outperform” rating to a “market perform” rating. They now have a $28.00 price target on the stock, down previously from $42.00.
  • 8/3/2017 – Teva Pharmaceutical Industries Limited was given a new $27.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 8/3/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at Oppenheimer Holdings, Inc. from an “outperform” rating to a “market perform” rating. They now have a $41.00 price target on the stock.
  • 8/3/2017 – Teva Pharmaceutical Industries Limited was given a new $39.00 price target on by analysts at Credit Suisse Group. They now have a “buy” rating on the stock.
  • 8/3/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at UBS AG from an “outperform” rating to a “market perform” rating.
  • 8/3/2017 – Teva Pharmaceutical Industries Limited had its “market perform” rating reaffirmed by analysts at CIBC.
  • 8/3/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $34.54 price target on the stock.
  • 8/2/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Mizuho. They now have a $30.00 price target on the stock.
  • 7/25/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They wrote, “MDCO announced early stoppage of the Ph 3 TANGO-2 trial for Vabomere (Carbavance) based on an interim analysis which showed a superior benefit-risk compared to best available therapy in serious infections due to CRE. We are impressed by DSMB stoppage of a trial with less than half of patients enrolled (72 out of the 150 target) suggesting a dramatic clinical benefit vs. standard of care. We believe today’s news provides a favorable setup for the August 21 (our estimate) PDUFA for Vabomere in cUTI. We continue to see Vabomere as a potential source of optionality for MDCO should management decide to launch this important new antibiotic on their own or in conjunction with a partner.””
  • 7/24/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $34.17 price target on the stock.

Teva Pharmaceutical Industries Limited (TEVA) traded down 0.47% during mid-day trading on Wednesday, hitting $17.11. The company had a trading volume of 16,364,698 shares. Teva Pharmaceutical Industries Limited has a one year low of $15.22 and a one year high of $51.51. The company’s market cap is $17.38 billion. The company’s 50 day moving average price is $18.13 and its 200-day moving average price is $28.20. Teva Pharmaceutical Industries Limited also was the target of some unusual options trading on Monday. Stock investors acquired 20,895 put options on the company. This represents an increase of approximately 103% compared to the average volume of 10,273 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. During the same quarter last year, the firm earned $1.25 EPS. The business’s revenue for the quarter was up 12.9% compared to the same quarter last year. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were paid a $0.085 dividend. The ex-dividend date of this dividend was Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a yield of 1.99%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is currently -15.36%.

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.